Search

The many obvious differences between simple and more complex multicellular organisms mask the extraordinarily high degree of conservation of the basic life processes and the proteins involved in them. The evolutionary conservation of many essential genes allows knowledge gained from mutational studies in simpler organisms to be used to identify the corresponding genes in mammals. The function of mammalian homologues can then be investigated by gene targeting in mice. Early development in the fruitfly Drosophila melanogaster is far more accessible to investigation than corresponding mammalian processes and many interesting genes involved in early development in this organism have been identified and isolated. Embryos carrying null alleles of the Drosophila melanogaster flightless I (fliI) gene exhibit only partial cellularization and gastrulation fails. Weak alleles of fliI result in adult flies lacking flight ability and exhibiting abnormal indirect flight muscle ultrastructure. The fliI gene was pos itionally cloned and the predicted protein of 1256 amino acids found to contain leucine-rich-repeat (LRR) and gelsolin-like domains. Homologues of fliI have subsequently been cloned from C. elegans, human (FLII) and mouse (Fliih) via PCR. FLII maps to 17p11.2, into a region affected in Smith-Magenis syndrome and in childhood primitive neuroectodermal tumours. The gelsolin domain interacts with G-actin in a Ca2+-independent manner, and has F-actin binding and severing activities. FLAP1 and FLAP2, novel ligands for the LRR domain detected in the yeast two-hybrid system, are derived from related mammalian genes. FLAP2 has been independently reported as an HIV-1 TAR RNA binding protein and as a transcriptional repressor. The LRR has been shown to interact with Ras both in vitro, and in vivo in yeast. Genomics-based studies on fliI and its homologues have opened up their involvement in a novel pathway of cytoskeletal regulation which appears to play an essential role in early development.

Cytochrophin-4 (cyt-4), a tetrapeptide with opioid-like activity, caused amnesia when injected into chick forebrain 5 hr after passive-avoidance training. Bilateral injections of cyt-4 directly into the lobus parolfactorius (LPO) resulted in the chicks being amnesic for the training task 24 hr later, whereas unilateral injections of cyt-4 were effective only when injected into the right LPO. Cyt-4-induced amnesia was reversed by the general opioid antagonist, naloxone, indicating that cyt-4 was acting via an opioid receptor. The mu- and delta-opioid receptors (but not kappa-opioid or ORL(1)-receptors) have been shown to be involved in memory formation 5 hr after training (). Because an antagonist of the mu-opioid receptor inhibited memory, we attempted to reverse the effect of cyt-4 using mu-opioid receptor agonists. Met[enk] was unable to reverse the inhibition of memory formation by cyt-4 suggesting that the mu-opioid receptor is not involved in this effect. However endomorphin-2 (endo-2) reversed the effect of cyt-4. We further investigated the action of endo-2 using an irreversible antagonist of the mu-receptor, beta-funaltrexamine (beta-FAN), and found that endo-2 reversed beta-FAN-induced amnesia indicating that endo-2 was not acting on the mu-opioid receptor in the chick. Because unilateral injections of beta-FAN were not amnesic (bilateral injections were amnesic) this provided further evidence that the effect of cyt-4 was not mediated via the mu-opioid receptor. Coinjection of the delta-receptor agonist, (D-Pen(2), L-Pen(5))enkephalin (DPLPE), reversed the disruptive effect of cyt-4 on memory. However, memory modulation via the delta-opioid receptor was not lateralized to the right hemisphere suggesting that cyt-4 does not act via this receptor either. It was shown that an antagonist of the epsilon-opioid receptor inhibited memory at the 5 hr time point. We conclude that the epsilon-opioid receptor or an unidentified opioid receptor subtype could be involved in the action of cyt-4.

Cyclosporine (CsA) inhibits release of interleukin 2 (IL-2) and hemopoietic growth activities such as interleukin 3 (IL-3) from major histocompatibility complex (MHC)-antigen-activated T cells. Production of both lymphokines appears to be coordinately regulated; the antigen dose response, T cell dose response, and time course of lymphokine appearance are similar. The triggering of lymphokine production by these cells is solely dependent on T cell-target cell interaction, as the T cell dose response curve indicates that no cooperation occurs between T cells, and any metabolic contribution by the target cell was eliminated by ultraviolet irradiation. This interaction triggers the transcription of lympho-kine-encoding mRNA. The process of lymphokine release can be divided into 4 steps: Antigen binds to the T cell; a signal is transferred to the cell nucleus; transcription of lymphokine-encoding mRNA occurs; and intact lymphokine is synthesized and secreted. CsA inhibits antigen triggered lymphokine production. However, it does not inhibit lymphokine release from the constitu-tively producing tumor cell lines WEHI-3 (which releases IL-3) and MLA 144 (which produces IL-2). Thus CsA has no effects on the lymphokine secretion process or any direct action upon lymphokine-coding mRNA. CsA does not affect antigen recognition during cell-mediated cytotoxicity. Therefore, CsA acts after antigen binding and before transcription of lymphokine-encoding mRNA. That is CsA blocks the transmission of the antigen signal. This information is used to show that this CsA-sensitive signal is required continuously to maintain the T cell in a lymphokine-secreting state.

The cDNA sequence for murine interleukin-3, one of the colony stimulating factors that regulate haematopoiesis, codes for a polypeptide of 166 amino acids including a putative signal peptide. The predicted amino acid sequence indicates that formation of mature interleukin-3 involves proteolytic removal of not only the signal peptide but additional ammo-terminal amino acids.

Human rIL-5 was found to selectively stimulate morphological changes and the function of human eosinophils. This molecule is thus a prime candidate for the selective eosinophilia and eosinophil activation seen in disease.

The human eosinophil differentiation factor (EDF) gene was cloned from a genomic library in lambda phage EMBL3A by using a murine EDF cDNA clone as a probe. The DNA sequence of a 3.2-kilobase BamHI fragment spanning the gene was determined. The gene contains three introns. The predicted amino acid sequence of 134 amino acids is identical with that recently reported for human interleukin 5 but shows no significant homology with other known hemopoietic growth regulators. The amino acid sequence shows strong homology (approximately 70% identity) with that of murine EDF. Recombinant human EDF, expressed from the human EDF gene after transfection into monkey COS cells, stimulated the production of eosinophils and eosinophil colonies from normal human bone marrow but had no effect on the production of neutrophils or mononuclear cells (monocytes and lymphoid cells). The apparent specificity of human EDF for the eosinophil lineage in myeloid hemopoiesis contrasts with the properties of human interleukin 3 and granulocyte/macrophage and granulocyte colony-stimulating factors but is directly analogous to the biological properties of murine EDF. Human EDF therefore represents a distinct hemopoietic growth factor that could play a central role in the regulation of eosinophilia.

Interleukin-3 (multi-CSF) is a multilineage haematopoietic growth regulator that initiates the proliferation and differentiation of multipotential stem cells1–5. Complementary DNA clones encoding interleukin-3 (IL-3) have recently been isolated6,7and the structure of the IL-3 gene determined8,9. IL-3 is produced by T lymphocytes or T lymphomas only after stimulation with antigens, mitogens or chemical activators such as phorbol esters. The myelomonocytic leukaemia line WEHI-3B10,11also produces IL-3 but its production is constitutive12–14and the WEHI-3B cells do not appear to produce significant levels of any of the other lymphokines normally secreted by T lymphocytes after stimulation. It has been proposed that the genetic change leading to the constitutive expression of IL-3 may have been a key event in the development of this leukaemia2,3,15,16. We report here that the constitutive synthesis of IL-3 by the WEHI-3B cell line is due to the insertion of an endogenous retrovirus-like element close to the 5′ end of the gene. The insertion, an intracisternal A particle (IAP) genome, is positioned with its 5′ long terminal repeat (LTR) close to the promoter region of the IL-3 gene, resulting in constitutive synthesis of IL-3.

A strain of Escherichia coli K-12 has been isolated that carries a Mu bacteriophage-induced mutation in the ent gene cluster. Nutritional tests together with examination of the compounds accumulated by the mutant strain indicated that the mutant was blocked both in the synthesis of 2,3-dihydroxy-benzoate and its subsequent conversion into enterochelin. Enzymic complementation assays of the mutant with several mutants each affected in one of the ent genes showed that the Mu-induced mutant was entA-, entB-, entC+, entD+, entE+, and entF+. Since the mutant produced the entD, entE, and entF gene products but was unable to produce enterochelin from 2,3-dihydroxybenzoate, it must therefore be affected in an additional protein concerned with this conversion. It is therefore postulated that the Mu-induced mutation affects a previously unrecognized gene, entG. Genetic experiments indicate that the mutation in strain AN462 which affects the three ent genes is the result of a single insertion of Mu in the ent gene cluster. This polarity mutant therefore provides evidence that three of the ent genes are part of an operon.

Mutants of Escherichia coliK-12 blocked in each of the three enzymatic reactions between chorismate and 2,3-dihydroxybenzoate, in the pathway leading to the iron-sequestering compound enterochelin, have been isolated and biochemically characterized. The three genes concerned (designated entA, entBand entC) have been shown to be clustered on the chromosome between purEand galand to be located near minute 14 by cotransduction with the purE, lip, and fepgenes. entA, entB, and entCwere shown to be the structural genes for 2,3-dihydro-2,3-dihydroxybenzoate dehydrogenase, 2,3-dihydro-2,3-dihydroxybenzoate synthetase, and isochorismate synthetase, respectively.

The ubiquinone precursors, 2-octaprenyl-6-methoxy-1,4-benzoquinone and 2-octaprenyl-3-methyl-6-methoxy-1,4-benzoquinone, were isolated from ubiquinone-deficient mutants of Escherichia coliand identified by nuclear magnetic resonance and mass spectrometry. Mutants accumulating 2-octaprenyl-6-methoxy-1,4-benzoquinone and 2-octaprenyl-3-methyl-6-methoxy-1,4-benzoquinone were shown to carry mutations in genes designated ubiEand ubiF, respectively. The ubiEgene was shown to be cotransducible with metE(minute 75) and close to two other genes concerned with ubiquinone biosynthesis. The ubiFgene was located close to minute 16 by cotransduction with the lip, gltA, and entAgenes.

Three mutant strains of Escherichia colihave been isolated which are lacking ferric-enterochelin esterase activity. This enzyme catalyzes the hydrolysis of the enterochelin moiety of ferric-enterochelin to yield ultimately three molecules of N-2,3-dihydroxybenzoylserine. The mutants (designated fes−) were shown to be unaffected in enterochelin biosynthesis, capable of enterochelin-mediated iron uptake, and able to utilize ferric-dihydroxybenzoylserine complexes normally. When grown under iron-deficient conditions, however, they showed an absolute requirement for added iron or citrate, a phenotype characteristic of mutants defective in some part of the enterochelin system of iron uptake. These results support the theory that iron, taken up by the cell as ferric-enterochelin is only available for general cell metabolism after hydrolysis of the ligand by enterochelin esterase. The three fes−strains were shown to be affected in the B component of enterochelin esterase. The fesBgene which is probably the structural gene coding for component B of the esterase, was shown to be located at about minute 14 on the E. colichromosome together with seven other genes involved in the enterochelin system of iron transport.

Two genes (ubiBand ubiD) concerned with two successive reactions in ubiquinone biosynthesis in Escherichia coliwere mapped and found to be closely linked. Mutant strains of E. colicarrying the ubiB−and ubiD−alleles were shown to accumulate 2-octaprenylphenol and 3-octaprenyl-4-hydroxybenzoic acid, respectively. These compounds were isolated and identified by using nuclear magnetic resonance and mass and infrared spectroscopy. Cell extracts from the mutant strain carrying the ubiD−allele lack 3-octaprenyl-4-hydroxybenzoate decarboxylase activity.

Seven ubiquinone-deficient mutants of Escherichia coli, each of which accumulates two phenolic precursors of ubiquinone, have been characterized, and the accumulated compounds have been identified. The mutants accumulate small quantities of 2-octaprenyl-6-methoxyphenol, which was isolated and characterized by nuclear magnetic resonance and mass spectrometry, and relatively large amounts of 2-octaprenylphenol, a compound previously identified from E. coli. They also accumulate small quantities of a compound identified as 2-(hydroxyoctaprenyl)phenol although the relevance of this compound to the biosynthesis of ubiquinone is not clear. The results of genetic analysis suggest that each of the mutants carries a mutation in a gene (designated ubiH) which is located at about min 56 on the E. colichromosome and is co-transducible with the serAand lysBgenes. Based on information obtained from this and previous studies with ubiquinone-deficient mutants, a pathway is proposed for ubiquinone biosynthesis in E. coli, and a summary of the known gene-enzyme relationships is given.

Three ubiquinone-deficient mutants of Escherichia coliunable to convert 4-hydroxybenzoate into 3-octaprenyl-4-hydroxybenzoate were isolated and examined. The results of genetic analysis suggest that each of the mutants carries a mutation in a gene designated ubiAwhich can be represented at minute 79 on the E. colichromosome map. The conversion of 4-hydroxybenzoate into 3-octaprenyl-4-hydroxybenzoate, catalyzed by 4-hydroxybenzoate octaprenyltransferase, was studied with a strain of E. colithat is blocked in the common pathway of aromatic biosynthesis and consequently accumulates the precursor of the side chain of ubiquinone. Both the side-chain precursor and 4-hydroxybenzoate octaprenyltransferase were shown to be membrane-bound. The enzyme required Mg2+for optimal activity. The ubiA−mutants were found to lack 4-hydroxybenozate octaprenyltransferase activity, which suggested that the ubiAgene is the structural gene coding for this enzyme.